<DOC>
	<DOC>NCT01407848</DOC>
	<brief_summary>In this study we will prospectively analyze the benefit of inhaled furosemide for preterm and term neonates with Transient Tachypnoea.</brief_summary>
	<brief_title>Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea</brief_title>
	<detailed_description>In this study we will prospectively analyze the benefit of inhaled furosemide for preterm and term neonates with transient Tachypnoea. Patients received nebulised Furosemide iv solution 1 mg/kg or nebulised 0,9% saline (4x/d) under blind conditions in random order so long as need a CPAP-treatment but max. 3 days. 20 Patient will be treating. The benefit will be measured as reduction of dyspnea, respiratory rate, oxygen demand and time on CPAP.</detailed_description>
	<mesh_term>Transient Tachypnea of the Newborn</mesh_term>
	<mesh_term>Tachypnea</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Neonates with 35+039+0 GA on the first day of life with the clinical diagnosis of Transient Tachypnoea The need for CPAP &gt;6 h to obtain the oxygen saturation &gt;92% Written informed consent of parent/guardian Systemic infection Intubation and mechanical ventilation before Inclusion in the trail Malformation and any other several disease with disturb of respiratory Subjects participating in other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>